[1126] Stromal Signatures in Endometrioid Endometrial Carcinomas
Inigo Espinosa, Emanuela D´Angelo, Ana Mozos, Belen Canet, Luis Catasus, Jaime Prat. Hospital de la Santa Creu i Sant Pau. Institute of Biomedical Research (IIB Sant Pau). Autonomous University of Barcelona, Barcelona, Spain
Background: The pattern of myometrial invasion in endometrioid carcinomas varies considerably; i.e., from widely scattered glands and cell nests, often associated with stromal desmoplasia, to invasive glands with little or no stromal response. Recently, two distinct stromal signatures, derived from a macrophage-response (CSF1) and a fibroblastic-response (DTF), were identified in breast carcinomas and correlated with clinicopathologic features including outcome. In this study, we explored whether these stromal signatures also apply to endometrioid carcinomas and if the aforementioned expression patterns correlated with morphologic changes.
Design: Stromal signatures were studied by immunohistochemistry on a tissue microarray of 88 endometrioid carcinomas. A case was considered to carry the CSF1-response signature if it showed coordinate expression of CD163, CD16, and CD32. Similarly, co-expression of SPARC and MMP11 was required for inclusion in the DTF-stromal signature group.
Results: Desmoplasia correlated positively with DTF expression signature. Likewise, CSF1 expression signature correlated strongly with the presence of mononuclear infiltrate. The DTF and CSF1 groups accounted for 17 % each of the total (15 of 88). Another 12 cases were positive for both DTF and CSF1 signatures (12/88; 13%). However, over half of the cases (46/88; 53%) failed to express any of the stromal signatures.
| Macrophage response signature (CSF1) | Fibroblast response signature (DTF) | Cases (%) |
| + | - | 15/88 (17%) |
| - | + | 15/88 (17%) |
| + | + | 12/88 (13%) |
| - | - | 46/88 (53%) |